4/19, 2023 Nakamura et al. at O-Force LLC have shown that short peptides (GSGNR, GSGFK) prevent the aggregation of amyloid-β, which causes Alzheimer's disease, and improve memory impairment in a mouse model of the disease.
December 31, 2023
Nakamura, R., Konishi, M., Higashi, Y. et al. Five-mer peptides prevent short-term spatial memory deficits in Aβ25-35-induced Alzheimer’s model mouse by suppressing Aβ25-35 aggregation and resolving its aggregate form. Alz Res Therapy 15, 83 (2023).
9/25, 2023 Recanemab has been approved by the MHLW for the treatment of Alzheimer's disease; will O-Force's short peptide (JAL-TA9) in development be a safer and cheaper fundamental treatment beyond recanemab?
December 23, 2023
The short peptide we are developing (JAL-TA9) is expected to be used as a safe and inexpensive fundamental treatment for AD beyond lecanemab, as shown in the table below.